JFC [JPMORGAN CHINA REGION FUND,] NSAR-B: (Original Filing)
[EX-99.77B ACCT LTTR 2 jfchinaauditletter.htm]
JFC [JPMORGAN CHINA REGION FUND,] NSAR-B: EX-99.77B ACCT LTTR 2 jfchinaauditletter.htm
[EX-99.77B ACCT LTTR 2 jfchinaauditletter.htm]
JFC [JPMORGAN CHINA REGION FUND,] NSAR-B: (Original Filing)
[jfchinaauditletter.htm 2 EX-99.77B ACCT LTTR]
JFC [JPMORGAN CHINA REGION FUND,] NSAR-B: jfchinaauditletter.htm 2 EX-99.77B ACCT LTTR
[jfchinaauditletter.htm 2 EX-99.77B ACCT LTTR]
BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)
[Biostar Pharmaceuticals, Inc. Announces 2010 Guidance: Revenues of $69 to $71 million and Net Income $16.2 to $17 million XIANYANG, China, March 1, 2010 (Xinhua-PRNewswire-FirstCall) Biostar forecasts revenues of $69.0 to $71.0 million with net income of $16.2 million to $17 million, excluding any non-cash charges. Management anticipates sales of its flagship product, Xin Aoxing, will represent approximately 68% to]
BSPM [Biostar Pharmaceuticals,] 8-K: Biostar Pharmaceuticals, Inc. Announces 2010 Guidance: Revenues of
[Biostar Pharmaceuticals, Inc. Announces 2010 Guidance: Revenues of $69 to $71 million and Net Income $16.2 to $17 million XIANYANG, China, March 1, 2010 (Xinhua-PRNewswire-FirstCall) Biostar forecasts revenues of $69.0 to $71.0 million with net income of $16.2 million to $17 million, excluding any non-cash charges. Management anticipates sales of its flagship product, Xin Aoxing, will represent approximately 68% to]
BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)
[Biostar Pharmaceuticals, Announces 2010 Guidance: Revenues of $69 to $71 million and Netome $16.2 to $17 million XIANYANG, China, March 1, 2010 (Xinhua-PRNewswire-FirstCall) Biostar forecasts revenues of $69.0 to $71.0 million with netome of $16.2 million to $17 million, excluding any non-cash charges. Management anticipatesles of its flagship product, Xin Aoxing, will represent approximately 68%]
BSPM [Biostar Pharmaceuticals,] 8-K: Biostar Pharmaceuticals, Announces 2010 Guidance: Revenues of $69
[Biostar Pharmaceuticals, Announces 2010 Guidance: Revenues of $69 to $71 million and Netome $16.2 to $17 million XIANYANG, China, March 1, 2010 (Xinhua-PRNewswire-FirstCall) Biostar forecasts revenues of $69.0 to $71.0 million with netome of $16.2 million to $17 million, excluding any non-cash charges. Management anticipatesles of its flagship product, Xin Aoxing, will represent approximately 68%]
PWRD [Perfect World] 6-K: (Original Filing)
[Perfect World Co., Ltd. ELVIN ING EE AU Kelvin Wing Kee Lau Chief Financial Officer 2]
PWRD [Perfect World] 6-K: Perfect World Co., Ltd. ELVIN ING EE AU
[Perfect World Co., Ltd. ELVIN ING EE AU Kelvin Wing Kee Lau Chief Financial Officer 2]
